1. Bevacizumab therapy leads to reduced vessel density and increased Ang‐2 expression
Bevacizumab therapy leads to reduced vessel density and increased Ang‐2 expression A–EImmunohistochemistry stainings with antibodies directed against CD31 (A) and Ang‐2 (B) in treatment‐naive GBM, post‐radiochemotherapy (S/RTx/CTx), and post‐radiochemotherapy + bevacizumab (S/RTx/CTx/Bev) therapy are displayed. Quantitative analyses of microvessel densities and Ang‐2+ vessels are shown in (C) and (D). The ratio of Ang‐2+ versus CD31+ vessels was determined in (E). Scale bars: 200 μm (A), 100 μm (B).FWestern Blot and corresponding quantification of CD31 and Ang‐2 in control and aflibercept‐treated mice (n = 5 each).G–ICAIX staining of treatment‐naive GBM and S/RTx/CTx/Bev patients. Analyses of hypoxic (CAIX+) area with regard to the whole tumor in human GBM (H). Tumor‐infiltrating lymphocytes (CD8/CD3) in human patients (I). Scale bar: 100 μm.Data information: Kruskal–Wallis (C–E, H–I). *P < 0.05, **P < 0.01, ***P < 0.005; treatment‐naive GBM n = 26, S/RTx/CTx n = 7, S/RTx/CTx/Bev n = 29; t‐test (F); data are mean ± SEM.
Alexander Scholz et al. EMBO Mol Med. 2016;8:39-57
© as stated in the article, figure or figure legend